Single lysophosphatidylcholine components exhibit adjuvant activities in vitro and in vivo

Clinical and Vaccine Immunology

Volumn 17, Issue 3, 2010, Pages 429-438

  Bach, Guillaume ^a,b,c,d   Perrin Cocon, Laure ^b,c,d   Gerossier, Estelle ^a   Guironnet Paquet, Aurélie ^b,c,d,e   Lotteau, Vincent ^b,c,d,e   Inchauspé, Geneviève ^a   Fournillier, Anne ^a  

^a TRANSGENE S A   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; HELICASE; HEPATITIS B SURFACE ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 5; INTERLEUKIN 6; LYSOPHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG ACTIVITY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYSOPHOSPHATIDYLCHOLINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES;

EID: 77649252013     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00420-09     Document Type: Article

References (24)

1. Aguilar, J. C., and E. G. Rodriguez. 2007. Vaccine adjuvants revisited. Vaccine 25:3752-3762.
2. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today 15:74-80.
3. Braun, L. J., A. Tyagi, S. Perkins, J. Carpenter, D. Sylvester, M. Guy, D. Kristensen, and D. Chen. 2009. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 27:72-79.
4. Cabana, V. G., J. N. Siegel, and S. M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30:39-49.
5. Coutant, F., S. Agaugue, L. Perrin-Cocon, P. Andre, and V. Lotteau. 2004. Sensing environmental lipids by dendritic cell modulates its function. J. Immunol. 172:54-60.
6. Coutant, F., L. Perrin-Cocon, S. Agaugue, T. Delair, P. Andre, and V. Lotteau. 2002. Mature dendritic cell generation promoted by lysophosphatidylcholine. J. Immunol. 169:1688-1695.
7. Dustin, M. L., and T. A. Springer. 1991. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu. Rev. Immunol. 9:27-66.
8. Fournillier, A., E. Gerossier, A. Evlashev, D. Schmitt, B. Simon, L. Chatel, P. Martin, N. Silvestre, J. M. Balloul, R. Barry, and G. Inchauspe. 2007. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVAbased candidate vaccine induces potent, long lasting and in vivo crossreactive T cell responses. Vaccine 25:7339-7353.
9. Glenny, A. T., C. G. Pope, H. Waddington, and U. Wallace. 1926. Immunological notes XVII-XXIV. J. Pathol. Bacteriol. 29:31-40.
10. Gouwy, M., S. Struyf, P. Proost, and J. Van Damme. 2005. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 16:561-580.
11. Gupta, R. K. 1998. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32:155-172.
12. Lindblad, E. B. 2004. Aluminium adjuvants-in retrospect and prospect. Vaccine 22:3658-3668.
13. Miyanohara, A., A. Toh-e, C. Nozaki, F. Hamada, N. Ohtomo, and K. Matsubara. 1983. Expression of hepatitis B surface antigen gene in yeast. Proc. Natl. Acad. Sci. U. S. A. 80:1-5.
14. Penin, F., J. Dubuisson, F. A. Rey, D. Moradpour, and J. M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39:5-19.
15. Perrin-Cocon, L., S. Agaugue, F. Coutant, P. Saint-Mezard, A. Guironnet-Paquet, J. F. Nicolas, P. Andre, and V. Lotteau. 2006. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 24:1254-1263.
16. Perrin-Cocon, L., F. Coutant, S. Agaugue, S. Deforges, P. Andre, and V. Lotteau. 2001. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J. Immunol. 167:3785- 3791.
17. Ryborg, A. K., B. Deleuran, H. Sogaard, and K. Kragballe. 2000. Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. Acta Derm. Venereol. 80:242-246.
18. Schijns, V. 2006. Unraveling "the immunologist's dirty little secret." In V. E. J. C. Schijns and D. T. O'Hagan (ed.), Immunopotentiators in modern vaccines. Elsevier Academic Press, Amsterdam, The Netherlands.
19. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:20963-20966.
20. Steinbrecher, U. P., and P. H. Pritchard. 1989. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 30:305-315.
21. Subbaiah, P. V., C. H. Chen, J. D. Bagdade, and J. J. Albers. 1985. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J. Biol. Chem. 260:5308-5314.
22. Ulmer, J. B., U. Valley, and R. Rappuoli. 2006. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24:1377-1383.
23. Witztum, J. L., and D. Steinberg. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792.
24. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.